Burson-Marsteller names Cohen new global chair

Share this article:
Burson-Marsteller has appointed Gail Cohen to global chair of the firm's healthcare practice. Cohen will report to Mark J. Penn, worldwide president and CEO. Cohen's new role began May 5.

“Gail has pioneered some of the industry's most successful pharmaceutical campaigns and has led numerous award-winning programs,” said Penn in a statement. “Her outstanding leadership skills and tremendous spirit will be essential to expanding our global healthcare practice, and vital to the quality of client service Burson-Marsteller is known for delivering across the globe.”

Cohen's responsibilities will include helping Burson-Marsteller's global healthcare practice strategically grow into new areas and drive success across regions, according to the statement. Prior to Burson-Marsteller, Cohen served on the Leadership Council for Chandler Chicco Companies (CCC). 

At CCC, she was responsible for driving new business initiatives, overseeing the agency's affiliate relationships with Asia-Pacific and the Americas, and assisting in creating unique branding platforms such as Buzz Matrix and Viractive. 

Additionally, Cohen led domestic and global campaigns at CCC for clinical development, scientific studies, patient advocacy, opinion leader relationships and life cycle management. Prior to joining CCC, she worked for boutique agencies focusing on consumer communications ranging from luxury goods to celebrity clients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.